Clinical efficacy of temozolomide and bevacizumab combined with concurrent radiotherapy in treatment of elderly patients with malignant glioma
10.3760/cma.j.issn.1006-9801.2018.01.010
- VernacularTitle:替莫唑胺联合贝伐单抗同步放疗治疗中老年恶性脑胶质瘤患者效果观察
- Author:
Jie BAI
1
;
Quanhua ZHANG
;
Lingyi GAO
;
Zhiyun LI
;
Chen GAO
Author Information
1. 730070,兰州军区总医院安宁分院检验科
- Keywords:
Glioma;
Drug therapy;
combination;
Bevacizumab;
Temozolomide;
Radiotherapy;
computer-assisted
- From:
Cancer Research and Clinic
2018;30(1):47-50
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of bevacizumab and temozolomide combined with concurrent radiotherapy for elderly patients with malignant brain glioma after the surgery . Methods A total of 55 patients in department of neurosurgery of Lanzhou Military Region General Hospital from January 2013 to December 2015 were enrolled. The patients were divided into control group and observation group. The 25 cases in the control group received radiotherapy and temozolomide. The 30 cases in the observation group received bevacizumab and temozolomide combined with concurrent radiotherapy. After treatment for 6 and 12 months, the clinical effects and adverse reactions of the two groups were compared byχ2 test, and the survival was compared by Log-rank test . Results Patients in the treatment group were followed up for 6 months after chemoradiotherapy, the response rate (RR) was 80 ％ (24/30), the disease control rate (DCR) was 97 ％ (29/30). The RR and DCR in the control group were 68 ％ (17/25) and 84 ％(21/25). There were significant differences between the two groups (χ2 values were 3.742 and 8.000, both P<0.05). After 12 months of follow-up, the RR and DCR in the treatment group were 40 ％ (12/30) and 80 ％(24/30), the control group were 16％(4/25) and 56％(14/25). There were significant differences between the two groups (χ2 values were 3.547 and 1.983, both P< 0.05). The adverse effect rates had no significant difference between the two groups (all P> 0.05). The 2-year survival rates in the treatment group and control group were 28.2 ％ and 11.0 ％, the difference was statistically significant (χ 2 = 4.512, P = 0.034). Conclusions Temozolomide and bevacizumab combined with concurrent radiotherapy in treatment of malignant glioma is superior to temozolomide combined with radiotherapy, and bevacizumab is safe and has few side effects. It is a preferred treatment and is worthy of clinical promotion.
